Caris Mpi
Caris Mpi is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects with BRAF-V600 Mutant Solid Tumors.
Sponsor C4 Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The Phase 2 dose-expansion phase was not initiated.
- A 12 April 2023 protocol amendment revised prior-anticancer-therapy eligibility from requiring BRAFi-naive participants to requiring prior BRAFi treatment when appropriate.
- A 6 February 2024 protocol amendment added CFT1946 plus cetuximab arms for BRAF V600-mutant colorectal cancer and updated enrollment stopping rules and eligibility criteria.
These findings describe the trial, not the service provider’s performance or responsibility.
A multicenter, open-label, non-randomized Phase 1/2 study to assess safety, tolerability, and imaging characteristics of [68Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [177Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors
Sponsor ITM Oncologics GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in patients with advanced non-squamous NSCLC who have progressed on standard of care immune checkpoint therapy and platinum doublet chemotherapy or standard immunotherapy without chemotherapy (PULMO-01).
Sponsor iOnctura SA
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (eNRGy)
Sponsor Partner Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma
Sponsor iOnctura SA
- Start (EU)
- Latest update
- Estimated end
An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumors
Sponsor Hotspot Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Sponsor Apollomics Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
Sponsor Bergenbio ASA
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Caris Mpi?
The 2026-10-09 snapshot links Caris Mpi to 9 distinct CTIS trials. Recorded services include Laboratory services, ctDNA analysis, DNA/RNA sequencing, Patient Recruitment/Retention Service Provider, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Caris Mpi?
The most frequently recorded therapeutic areas are Respiratory, Solid Tumor Oncology, Endocrinology, Gastroenterology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Caris Mpi conducted?
The linked trials record locations in 14 countries, including Spain, Italy, France, Belgium, Germany. These are trial locations, not confirmed office locations or countries where Caris Mpi delivered services.
What can this page tell me about Caris Mpi's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Caris Mpi. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Caris Mpi Inc.